Strategy for Developing a Stable CHO Cell Line that Produces Large Titers of Trastuzumab Antibody
Background: Trastuzumab (Herceptin®) is currently the main treatment option for breast cancer patients that overexpress the human epidermal growth factor receptor 2 (HER2). This antibody binds specifically to HER2, blocks cancer cell growth, and promotes effective cell death. In the present study, w...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-11-01
|
| Series: | Frontiers in Bioscience-Elite |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBE/15/4/10.31083/j.fbe1504024 |